Athira Pharma shares are trading lower after the company announced its Alzheimer's candidate failed to improve cognition and function in patients with mild/moderate disease.
Portfolio Pulse from Benzinga Newsdesk
Athira Pharma's Alzheimer's drug candidate failed to show improvement in cognition and function in patients with mild to moderate disease, leading to a decline in its stock price.
September 04, 2024 | 2:28 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Athira Pharma's Alzheimer's drug candidate did not meet its primary endpoints in clinical trials, resulting in a negative impact on the stock price.
The failure of the Alzheimer's drug candidate to improve cognition and function is a significant setback for Athira Pharma, as it directly affects the company's potential revenue from this product. This news is likely to lead to a decrease in investor confidence and a drop in the stock price.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100